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Abstract
Background:  Polymorphisms within the insulin gene can influence insulin expression in the
pancreas and especially in the thymus, where self-antigens are processed, shaping the T cell
repertoire into selftolerance, a process that protects from β-cell autoimmunity.
Methods: We investigated the role of the -2221Msp(C/T) and -23HphI(A/T) polymorphisms
within the insulin gene in patients with a monoglandular autoimmune endocrine disease [patients
with isolated type 1 diabetes (T1D, n = 317), Addison's disease (AD, n = 107) or Hashimoto's
thyroiditis (HT, n = 61)], those with a polyglandular autoimmune syndrome type II (combination of
T1D and/or AD with HT or GD, n = 62) as well as in healthy controls (HC, n = 275).
Results:  T1D patients carried significantly more often the homozygous genotype "CC" -
2221Msp(C/T) and "AA" -23HphI(A/T) polymorphisms than the HC (78.5% vs. 66.2%, p = 0.0027
and 75.4% vs. 52.4%, p = 3.7 × 10-8, respectively).
The distribution of insulin gene polymorphisms did not show significant differences between
patients with AD, HT, or APS-II and HC.
Conclusion: We demonstrate that the allele "C" of the -2221Msp(C/T) and "A" -23HphI(A/T)
insulin gene polymorphisms confer susceptibility to T1D but not to isolated AD, HT or as a part
of the APS-II.
Background
Type 1 diabetes (T1D) has a multifactorial pathogenesis,
partly caused by environment but also by genetic predis-
position. The association of the MHC class II genes with
T1D is well known, but there are also non- MHC genes
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such as the insulin gene, that confer susceptibility to T1D
[1].
The insulin gene is transcribed upon binding of the tran-
scription factor Pur1 to the promoter element, known as
the variable number of tandem repeat (VNTR) region,
located 596 bp upstream of the insulin gene translation
initiation site. The VNTR region comprises variable 14–15
bp tandem repeat sequences with the consensus 5'-ACAG-
GGGTGTGGGG-3', also named the insulin gene minisat-
ellite. In Caucasians there are two main classes of the
VNTR region minisatellites named class I and class III alle-
les. The VNT
R class I alleles, which are associated with increased sus-
ceptibility to T1D, comprise between 26 and 63 repeat
units and are shorter than class III alleles (between 141
and 209 repeat units), associated with dominant protec-
tion. The class II alleles are very rare in Caucasians but
common in Africans [2-5].
Polymorphisms within the insulin gene are in linkage dis-
equilibrium with the VNTR region and can therefore be
used as markers for these gene variants. The allele "C" of
the -2221 MspI polymorphism of the insulin promoter
region has been shown to be in strong linkage with the
class I allele of the VNTR region and the variant "T" with
the class III alleles [6,7]. Therefore this polymorphism can
be used as a marker for this gene segment [8].
Recent studies of the insulin gene locus showed the -
23HphI (A/T) and the +1140 (A/C) polymorphisms to
confer the strongest susceptibility to T1D [4,9]. Further-
more polymorphisms of the insulin gene are associated
with different regulation of insulin expression in target tis-
sues such as the pancreas and especially in the thymus,
where the expression of self-antigens shapes and main-
tains a self tolerant T cell repertoire [10,11].
T1D and Addison's disease (AD) may occur in the same
patient to form a polyglandular syndrome type II (APS-II)
[12]. Although the precise function of the VNTR is uncer-
tain, it is conceivable that through its potential effect on
the thymic expression level of insulin, the VNTR could
affect the development of immune self tolerance not only
to antigenic peptides derived from insulin but also to
other endocrine targets: this could occur through local
insulin signalling by affecting other genes' expression lev-
els thereby leading to differences in thymic expression lev-
els of thyroid or other endocrine antigens. Therefore the
VNTR region could confer susceptibility not only to T1D
but also to other autoimmune endocrine disease such as
Addison's disease (AD), Hashimoto's thyroiditis (HT) or
Graves' disease (GD) by causing an abnormal thymic tol-
erance [13].
Therefore we investigated the role of the the -2221Msp(C/
T) and -23HphI(A/T) insulin gene polymorphisms in
patients with isolated T1D, AD and HT and in patients
with a APS-II [T1D and/or AD and at least one of the dis-
orders HT or GD] as well as in healthy controls (HC).
Methods
Subjects
All patients were recruited from the endocrine outpatient
clinics at the University Hospitals Frankfurt am Main,
Freiburg, Würzburg, Munich and Düsseldorf (Germany).
Altogether 1248 individuals were genotyped for the -2221
(C/T) polymorphism within the promoter region of the
insulin gene [485 with a monoglandular autoimmune
disease, 317 patients with T1D (of these 213 with par-
ents), 107 with AD and 61 with HT, 62 with APS-II and
275 HC].
T1D
T1D was diagnosed according to World Health Organiza-
tion criteria. The median age of disease onset was 10 years
(range 1–50 years). From the 213 T1D families, 17 off-
spring had T1D as a part of the APS-II. There was no evi-
dence for MODY- or other rare forms of insulin-deficient
diabetes, furthermore all were simplex cases.
Patients with isolated T1D may develop other autoim-
mune diseases in the future. Nevertheless, at the point of
this study, they had the diagnosis of isolated T1D.
AD
Addison's disease was diagnosed by primary adrenal fail-
ure without evidence of tuberculosis or adrenoleukodys-
trophy. Adrenal autoantibodies were detected with
indirect immunofluorescence on cryostat sections; these
were confirmed to be directed against 21-hydroxylase in a
subgroup of patients by radioimmunoassay. No neuro-
logical deficits could be detected. No patients with AD
without T1D had antibodies against β-cell antigens (GAD-
Ab or IA-2 Ab).
HT
The diagnosis of HT was established by positive thyre-
oglobulin (Tg) and/or thyroid peroxidase antibodies,
reduced echogenicity on thyroid ultrasound, and normal
or elevated thyrotropin (TSH) levels.
APS-II
Patients with an APS-II (n = 62) were diagnosed as a com-
bination of T1D or AD and other of the above mentioned
disorders.
Among the patients with APS-II, there were 22 patients
with the diagnosis T1D and autoimmune thyroidtis (AIT)BMC Medical Genetics 2008, 9:65 http://www.biomedcentral.com/1471-2350/9/65
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(15 with T1D and HT and 7 with T1D and GD), 33 with
AD and AIT (23 with AD and HT and 10 with AD and GD)
as well as 7 with T1D, AD and HT.
The diagnosis of GD rested on autoimmune hyperthy-
roidism with elevated TSH receptor autoantibodies and/
or ophthalmopathy.
HC
Age- and sex-matched HC were volunteer blood-donors
from the Red Cross Blood Transfusion Centre in Frankfurt
am Main (Germany), staff personal or medical students
from the University Hospital Frankfurt am Main (Ger-
many) without family history of T1D, HT, GD or AD.
Although the adrenal function of the controls was not for-
mally assessed, they had normal thyroid function and
were thyroid autoantibody negative and did not report
clinical symptoms.
All individuals were of German origin and were inhabit-
ants from the surrounding area of Frankfurt am Main
(Germany).
The male: female ratio of patients with T1D, AD, HT, APS-
II and HC was 1:0.91, 1:2.14, 1:4.56, 1:3.89 and 1:0.48,
respectively. The median age of the patients with T1D, AD,
HT, APS-II and HC was 30 (range 5–81), 57 (range 22–
92), 52 (range 25–95), 46 (range 15–76) and 40.5 (range
23–83), respectively.
The study protocol was approved by the Ethics Committee
of the University Hospital, Frankfurt am Main and written
informed consent was obtained from all patients and con-
trols.
Genotype analysis
DNA was extracted from whole blood according to stand-
ard protocols and polymorphisms were typed according
to the following protocols:
-2221MspI (C/T)
Patients with T1D, HT and APS-II and HC were studied for
the insulin gene promotor polymorphism -2221 (C/T)
using polymerase chain reaction (primers: 5'-ACCCCAC-
TACACGCT GCTG-3' and 5'-CCCTTCAGAGACAC-
CCCCA-3') followed by digestion with the restriction
enzyme Msp I (New England Bio Labs, Beverly, MA, USA)
and separated on 4% agarose gel.
DNA of patients suffering from AD as well as of 100 sam-
ples of the above mentioned (which were genotyped by
restriction enzyme and chose at random to confirm the
accuracy of the method) were analyzed by real-time PCR
using ABI 7300 (Applied biosystems®). Primer and probe
sequences are as follows: forward primer: 5'-TGAGTAG-
GAGTTTGCCAGTGTTG-3'; reverse primer: 5'-GCTGCT-
GGGATCCTGGAT-3'; probe for T allele 5'-VIC-
TCAGCTCCCTGGCCGA-3' and probe for C allele 5'-FAM-
AGCTCCCCGGCCGA-3'.
-23HphI (T/A)
All samples were genotyped by real time PCR by using
C_1223317-Assay (Applied biosystems®). In order to
check the accuracy of the method 100 DNA-samples –
chosen at random- were genotyped according to a previ-
ously published [14].
Statistical analysis
Patients and controls were compared using allele-wise
and genotype-wise Chi2 testing by using BiAS software
(package 7.01, Epsilon, Weinheim, Germany) [15].
The transmission disequilibrium test (TDT) was used for
the family analysis to detect preferential transmission of
the alleles to affected offspring [16] as well as to analyze
the interaction between HLA and the -2221 polymor-
phism using Haploview software version 3.2 available
from the website [17].
In order to detect a statistical difference (p < 0.05) at an
OR 1.8 (as seen for T1D) we calculated for the -
2221Msp(C/T) SNP that 276 chromosomes (138 patients
vs. 138 HC) and for -23HphI(A/T) 224 chromosomes
(112 patients vs. 112 HC) are necessary to reach a power
of 80%- using the software version 2.1.30 [18].
P values were corrected by the number of polymorphisms
(n = 2). A corrected p (pc) < 0.05 was considered signifi-
cant.
Results
We found a significant difference in the genotype and
allele distribution of both -2221Msp and -23HphI poly-
morphisms between patients with T1D and HC.
Thus T1D patients carried significantly more often the
genotypes "CC" of the -2221MspI and "AA" of the -
23HphI polymorphisms, respectively than the HC
(78.5% vs. 66.2%, p = 0.0027 and 75.4% vs. 52.4%, p =
3.7 × 10-8, respectively, table 1 and 2).
Heterozygous parents in T1D families transmitted signifi-
cantly more often the allele "C" and "A" of the -2221MspI
and -23HphI polymorphisms to their affected offspring
(73.8% vs. 26.2 %, p = 9.0 × 10-8 and 3.3 × 10-8, respec-
tively; data not shown), matching our findings from the
case-control analysis.BMC Medical Genetics 2008, 9:65 http://www.biomedcentral.com/1471-2350/9/65
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The -23HphI polymorphism showed the strongest associ-
ation to T1D in both T1D-family and case-control analy-
sis.
Neither genotype frequencies nor allele wise comparison
differed between patients with HT, AD, APS-II and HC
(table 1 and 2). No interaction was found when AD
Table 1: Distribution of genotypes of the -2221 (C/T) insulin polymorphism in German patients with autoimmune endocrinopathies 
and healthy controls
Genotype
CC CT TT Allele
Group n n % n % n % p* C% T% p*
HC 275 182 66.2 85 30.9 8 2.9 81.6 18.4
T1D 317 249 78.5 64 20.2 4 1.3 0.0027 88.6 11.4 8.9 × 10-4
HT 61 36 59.0 22 36.1 3 4.9 0.4898 77.0 23.0 0.2998
AD 107 73 68.2 25 23.4 9 8.4 0.0331† 79.9 20.1 0.4738
APS-II 62 45 72.6 16 25.8 1 1.6 0.5870 85.5 14.5 0.3763
T1D + AIT 22 18 81.8 4 18.2 0 0 0.2898 90.9 9.1 0.2898
T1D + HT 15 13 86.7 2 13.3 0 0 0.2479 93.3 6.7 0.1653
T1D + GD 7 5 71.4 2 28.6 0 0 0.8851 85.7 14.3 0.9682
AD + AIT 33 22 66.7 10 30.3 1 3.0 0.9968 81.8 18.2 0.8948
AD + HT 23 15 65.2 8 34.8 0 0 0.6790 82.6 17.4 0.9723
AD + GD 10 7 70.0 2 20.0 1 10 0.3802 80.0 20.0 0.9138
T1D + AD + HT 7 5 71.4 2 28.6 0 0.0 0.8851 85.7 14.3 0.9682
P values are given uncorrected
*compared to healthy controls
†Not significant after correction
Table 2: Distribution of genotypes of the -23HphI (A/T) insulin polymorphism in German patients with autoimmune endocrinopathies 
and healthy controls
Genotype
AA AT TT Allele
Group n n % n % n % p* A% T% p*
HC 275 144 52.4 118 42.9 13 4.7 73.8 26.2
T1D 317 239 75.4 70 22.1 8 2.5 3.7 × 10-8 86.4 13.6 6.6 × 10-8
HT 61 32 52.5 29 47.5 0 0 0.2092 76.2 23.8 0.6623
AD 107 54 50.5 46 43.0 7 6.5 0.7641 72.0 28.0 0.6675
APS-II 62 35 56.5 23 37.1 4 6.5 0.6485 75.0 25.0 0.8746
T1D + AIT 22 16 72.7 5 22.7 1 4.5 0.1675 84.1 15.9 0.1848
T1D + HT 15 11 73.3 3 20.0 1 6.7 0.2159 83.3 16.7 0.3436
T1D + GD 7 5 71.4 2 28.6 0 0 0.5628 85.7 14.3 0.4873
AD + AIT 33 17 51.5 13 39.4 3 9.1 0.5572 71.2 28.8 0.7597
AD + HT 23 13 56.5 8 34.8 2 8.7 0.5870 73.9 26.1 0.8724
AD + GD 10 4 40.0 5 50.0 1 10 0.6242 65 35 0.5353
T1D + AD + HT 7 2 28.6 5 71.4 0 0.3087 64.3 73.8 0.6227
P values are given uncorrected
*compared to healthy controls
†Not significant after correctionBMC Medical Genetics 2008, 9:65 http://www.biomedcentral.com/1471-2350/9/65
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patients were stratified according to the HLA risk (data not
shown).
Discussion
In the present study, we demonstrate the allele "C" of the
-2221MspI and "A" of the -23HphI polymorphisms
within the insulin region to confer susceptibility to T1D in
German patients. Therefore our data are in line with pre-
vious reports, which found that the -2221 MspI SNP and
the -23HphI SNP are associated with T1D, where the -
2221 MspI SNP was only part of a susceptibility insulin
gene haplotype and the -23HphI SNP was found with the
strongest association to T1D [4,9].
Other studies found no evidence of excessive transmission
of the -23HphI polymorphism (equivalent to VNTR class
I) in patients with GD [19]. Also no association was dem-
onstrated of INS VNTR in patients with celiac disease and
AD from a Basque population [20]. Thus our present
study supports those findings suggesting that neither the -
2221 MspI nor the -23HphI polymorphisms are associ-
ated with isolated AD, HT or with GD as part of the APS-II.
Class III alleles of the insulin VNTR region are associated
with substantially higher insulin mRNA levels than VNTR
class I in the thymus presumably, causing a more efficient
deletion of insulin autoreactive T cells [13], explaining
their protective effect on T1D. On the other hand the "C"
allele of -2221 MspI has been associated with a decreased
insulin expression in the thymus, leading to less efficient
deletion of autoreactive insulin-specific T-cells [10]. This
may increase the risk to develop T1D. Likewise the protec-
tive effect of the "T" [2] allele could lead to higher level of
insulin transcription.
This association appears to be confined to patients with
T1D only and larger numbers are needed to rule out an
effect in patients with other immune components of T1D
associated with the APS-II. So far this locus may help to
differentiate the susceptibility to isolated T1D in compar-
ison to T1D predisposition loci that are shared with endo-
crine autoimmune disorders.
Conclusion
We demonstrate the allele "C" of the -2221MspI and "A"
of the -23HphI polymorphisms within the insulin region
confer susceptibility to T1D but not to isolated AD, HT or
as a part of the APS-II.
Abbreviations
T1D: Type 1 diabetes; VNTR: variable number of tandem
repeat; AD: Addison's disease; HT: Hashimoto's thyroidi-
tis (HT); APS-II: Polyglandular autoimmune syndrome
type II; GD: Graves' disease; HC: Healthy controls; TDT:
Transmission disequilibrium test; HLA: Human Leuko-
cyte Antigen.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
ER–L and BL carried out the genotyping of the patients
and controls. MP–M carried out the re-genotyping of the
patients and controls to confirm the accuracy of the
method. HK participated in the statistical analysis GM,
HSW, NR, SH and JS made the diagnosis and collaborated
in collection of samples. HK carried out statistical analy-
sis. ER–L and KB conceptualized and designed the study.
References
1. Cox NJ, Wapelhorst B, Morrison VA, Johnson L, Pinchuk L, Spielmann
RS, Todd JA, Concannon P: Seven regions of the genome show
evidence of linkage to type 1 diabetes in a consensus analysis
of 767 multiplex families.  Am J Hum Genet 2001, 69(4):820-830.
2. Pugliese A, Miceli D: The insulin gene in diabetes.  Diabetes Metab
Res Rev 2002, 18(1):13-25.
3. Stead JD, Buard J, Todd JA, Jeffreys AJ: Influence of the allele line-
age on the role of the insulin minisatellite in susceptibility to
type 1 diabetes.  Hum Mol Genet 2000, 9(20):2929-2935.
4. Barratt BJ, Payne F, Lowe CF, Hermann R, Healy BC, Harold D, Con-
cannon P, Gharani N, Mc Carthy MI, Olavesen MG, McCormack R,
Guja C, Ionescu-Tîrgovis ¸te C, Undlien DE, Rønningen KS, Gillespie
KM, Tuomilehto-Wolf E, Tuomilehto J, Bennett ST, Clayton DG,
Cordell HJ, Todd JA: Remapping the insulin gene/IDDM2 locus
in type 1 diabetes.  Diabetes 2004, 53(7):1884-1889.
5. Bell GI, Horita S, Karam JH: A polymorphic locus near the
human insulin gene is associated with insulin-dependent dia-
betes mellitus.  Diabetes 1984, 33(2):176-183.
6. Bennett ST, Lucassen AM, Gough SCL, Powell EE, Undlien DE, Pritch-
ard LE, Merriman ME, Kawaguchi Y, Dronsfield MJ, Pociot F, Nerup J,
Bouzekri N, Cambon-Thomsen A, Rønningen KS, Barnett AH, Bain
SC, Todd JA: Susceptibility to human type 1 diabetes at
IDDM2 is determined by tandem repeat variation at the
insulin minisatellite locus.  Nat Genet 1995, 9(3):284-293.
7. Haller K, Kisand K, Nemvalts V, Laine AP, Ilonen J, Uibo R: Type I
diabetes is insulin -and CTLA-4 +49 A/G polymorphism
dependent.  Eur J Clin Invest 2004, 34(8):543-548.
8. Laine AP, Hermann R, Knip M, Simell O, Akerblom HK, Ilonen J: The
human leukocyte antigen genotype has a modest effect on
the insulin gene polymorphism-associated susceptibility to
type 1 diabetes in the Finnish population.  Tissue Antigens 2004,
64(1):72-74.
9. Awata T, Kawasaki E, Ikegami H, Kobayashi T, Maruyama T, Nakanishi
K, Shimada A, Iizuka H, Kurihara S, Osaki M, Uga M, Kawabata Y, Tan-
aka S, Kanazawa Y, Katayama S: Insulin gene/IDDM2 locus in Jap-
anese type 1 diabetes: contribution of class I alleles and
influence of class I subdivision in susceptibility to type 1 dia-
betes.  J Clin Endocrinol Metab 2007, 92(5):1791-1795.
10. Pugliese A, Brown D, Garza D, Murchison D, Zeller M, Redondo M,
Diez J, Eisenbarth GS, Patel DD, Ricordi C: Self- antigen present-
ing cells expressing IDDM- associated autoantigens exist in
both thymus and peripheral lymphoid organs in humans.  J
Clin Invest 2001, 107(5):555-564.
11. Sarugeri E, Dozio N, Belloni C, Meschi F, Pastore MR, Bonifacio E:
Autoimmune responses to the beta cell autoantigen, insulin,
and the INS VNTR-IDDM2 locus.  Clin Exp Immunol 1998,
114(3):370-376.
12. Eisenbarth GS, Gottlieb PA: Autoimmune polyendocrine syn-
dromes.  New England Journal of Medicine 2004, 350(20):2068-2079.
13. Vafiadis P, Ounissi-Benkalha H, Palumbo M, Grabs R, Rousseau M,
Goodyer CG, Polychronakos C: Class III Alleles of the Variable
Number of Tandem Repeat Insulin Polymorphism associ-
ated with silencing of thymic insulin predispose to type 1 dia-
betes.  J Clin Endocrinol Metab 2001, 86(8):3705-3710.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medical Genetics 2008, 9:65 http://www.biomedcentral.com/1471-2350/9/65
Page 6 of 6
(page number not for citation purposes)
14. Adamson KA, Cheetham TD, Kendall-Taylor P, Seckl JR, Pearce SH:
The role of the IDDM2 locus in the susceptibility of UK APS1
subjects to type 1 diabetes mellitus.  Int J Immunogenet 2007,
34(1):17-21.
15. Ackermann H: Der Chi2-Vierfelder-Test.  In Biometrie  Volume
Chapter 5. 3rd edition. Hochheim. Darmstadt; 1999:75-79. 
16. Sham PC, Curtis D: An extended transmission/disequilibrium
test (TDT) for multi-allele marker loci.  Ann Hum Genet 1995,
59(3):323-336.
17.  [http://www.broad.mit.edu/mpg/haploview].
18.  [http://www.mc.vanderbilt.edu/prevmed/ps/index.htm].
19. Tait KF, Collins JE, Heward JM, Eaves I, Snook H, Franklyn JA, Barnett
AH, Todd JA, Maranian M, Compston A, Sawcer S, Gough SC: Evi-
dence for a type 1 diabetes-specific mechanism for the insu-
lin gene-associated IDDM2 locus rather than a general
influence on autoimmunity.  Diabet Med 2004, 21(3):267-270.
20. Pérez De Nanclares G, Bilbao JR, Calvo B, Vitoria JC, Vázquez F,
Castano L: 5'-Insulin gene VNTR polymorphism is specific for
type 1 diabetes: no association with celiac or Addison's dis-
ease.  Ann N Y Acad Sci 2003, 1005:319-323.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2350/9/65/prepub